GlassScriptPhysician profile
Tanveer Chaudhry
NPI 1932195823
$9,278.53
in general payments reported to CMS, 2019-2025
23 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2020: $689 · 2021: $138 · 2022: $180 · 2023: $2,900 · 2024: $2,763 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,137.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,638.59 | 2019-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $1,532.72 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,495.87 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $918.22 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $681.94 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $499.92 | 2020-2025 | Rexulti |
| Allergan, INC. | $376.38 | 2019-2020 | |
| Abbvie INC. | $355.93 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $351.33 | 2023-2025 | Auvelity, Sunosi |
| Indivior INC. | $240.85 | 2019-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $182.61 | 2023-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $159.33 | 2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $141.26 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $130.23 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $114.90 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $114.87 | 2023 | Trintellix |
| Corium, LLC | $83.32 | 2023-2024 | Azstarys |
| Almatica Pharma LLC | $83.18 | 2024-2025 | Loreev Xr |
| Sage Therapeutics, LLC | $74.74 | 2024 | |
| Idorsia Pharmaceuticals US INC | $41.43 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $23.00 | 2023 | Xelstrym |
| Braeburn INC. | $22.25 | 2024 | Brixadi |
| Avanir Pharmaceuticals, INC. | $15.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanveer Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.